Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on developing oncology therapeutics. The company's lead candidate, AN2025, is a pan-phosphoinositide 3-kinase inhibitor currently in Phase III trials for recurrent or metastatic head and neck squamous cell carcinomas. Its pipeline also includes AN0025, a prostaglandin E receptor 4 antagonist in Phase Ib testing for multiple indications including non-small cell lung cancer, urothelial cancer, triple-negative breast cancer, colorectal cancer, and cervical cancer in patients who have progressed on or after standard treatments. AN4005, an oral PD-L1 inhibitor in Phase I development, represents the company's approach to checkpoint inhibition through PD-L1 dimerization.
The company's earlier-stage programs include AN8025, a multifunctional antibody designed to modulate T cell and antigen-presenting cell activity, and AN9025, an oral pan-KRAS inhibitor in preclinical development. As a clinical-stage company, Adlai Nortye generates no revenue from product sales and relies on capital markets and other financing sources to fund operations.
Based in Grand Cayman, Cayman Islands, and incorporated in Delaware, the company operates with approximately 123 full-time employees. Adlai Nortye was founded in 2004 and is listed on Nasdaq with a market capitalization of approximately $0.4 billion.
No 10-K filings found.